Attending Biotech and Pharma
Speaker Profiles
Duncan B Judd, Manager, Discovery Medicinal Chemistry,
GlaxoSmithKline
Duncan obtained his B.Sc. (Kingston Polytechnic) and M. Phil. (CNAA) in England. He joined Glaxo Research Ltd. in 1972. His background is in Medicinal Chemistry particularly in 7TM-receptor research. He is an inventor on numerous patents in fields of research such as agonists of kappa-opioid, and prostaglandins, and antagonists of angiotensin, chemokine, and histamine receptors.
Duncan developed an interest in the design of libraries for lead generation. This resulted in him focusing on the design and acquisition of intermediates and compound synthesis. He now manages the outsourcing of chemistry services, for Discovery Medicinal Chemistry.
Dr Ming-Qiang Zhang, VP Research,
Biotica Technology Ltd
Ming-Qiang Zhang joined Biotica in March 2004 as Vice President of Research. Prior to joining Biotica, Dr Zhang was Director of Medicinal Chemistry at Shire Pharmaceuticals Group plc. Before Shire, he was Section Head of Medicinal Chemistry at Organon (Akzo-Nobel). Prior to joining the industry, he held academic positions at the Leiden-Amsterdam Center for Drug Research (LACDR). Dr Zhang is a co-founder of ViroChem Pharma Inc. in Montreal, Canada. He also holds an adjunct professorship at the Southern Medical University in China. During his career, Dr Zhang has led the discovery of multiple candidate drugs progressed to clinical development and is a (co-)author/inventor of over 100 scientific publications and patents. He is a recipient of 2007 RSC Malcolm Campbell Award in Biological and Medicinal Chemistry for the discovery of Sugammadex. Dr Zhang received his PhD in medicinal chemistry from the University of Antwerp (1990) and did his post-doctoral research at Vrije Universiteit Amsterdam.
Martin Cooper, Development Manager,
7TM Pharma A/S
Martin Cooper started his professional career in 1985 at the Medicinal Chemistry Department of Glaxo Group Research in Greenford, West London, but after 2 years moved to the Medicinal Chemistry Department at the Fisons Pharmaceuticals site in Loughborough, later to become AstraZeneca Charnwood. During the last 3 years at the Loughborough site he established a scale-up team, within the Discovery function, primarily responsible for bridging the gap between discovery lab- and kilo lab-scale synthesis for projects both at the Charnwood and Lund sites.
In 2005, a career move to 7TM Pharma in Denmark took Martin into the Medicon Valley Biotech Sector again to work within Medicinal Chemistry and after 2 years, as project chemistry leader, was heavily involved in the nomination of the company’s first small molecule pre-clinical candidate. In view of previous experience working at the interface between Discovery and Development, in 2007, he moved into the Development department and has since played a key role in all aspects of the small molecule pre-clinical program.
Dr Peter Hudson, Director of Pharmaceutical Development,
Acadia Pharmaceuticals AB
Dr Peter Hudson is Director of Pharmaceutical Development at ACADIA Pharmaceuticals AB in Malmö, Sweden and is responsible for all aspects of active substance development for ACADIA’s NCE pipeline.
Peter graduated from Nottingham University in 1988 and continued at Nottingham, completing his PhD in 1991. From there he spent 3 years as a postdoc with Professor Phillip Parsons at Reading University involved in the synthesis of the potent cardiotoxin batrachotoxin.
From there he took up a position at Ferring Research Institute in Southampton as a medicinal chemist, rising to Team Leader in 2000. In 2000 he also took responsibility for the API outsourcing of Ferring’s small molecule V2 agonist NCE, which brought him into close contact with Ferring’s Copenhagen-based development departments. In early 2003, Peter transferred to Copenhagen to take responsibility for the API outsourcing of all Ferring’s development projects. At the time of leaving, Peter was responsible for the API activities on five separate NCE projects, three of them peptidic molecules, including the recently filed prostate cancer therapeutic, degarelix. He was also involved in the API aspects of due diligence activities for Ferring.
In October 2006, Peter moved to ACADIA to take up the position of Director of Pharmaceutical Development covering a number of compounds in the CNS area. Responsibility areas have covered drug substance and drug product development, analytics and clinical trial supply management.
For the last two years, Peter has participated on the Danish Medicademy Regulatory Affairs professional training course, lecturing on drug substance synthesis aspects and drug substance characterization.
Dr Roland Collicott, Senior Consultant,
ChalPharm Consultancy
Heading up the ChalPharm Consultancy, Dr Roland Collicott provides assistance to the pharmaceutical industry in the areas of chiral analysis, polymorphic characterisation, stability studies, chemical analysis in a GMP environment, specifications and all aspects of international CMC documentation. He also runs training courses to cover many areas of analytical chemistry, particularly in chromatography, chiral and polymorphic analysis. He has served as an expert witness and consulted in trials in Canada, UK and Germany.
Before founding the ChalPharm Consultancy in 2005, Roland was Analytical Section manager at OSI Pharmaceuticals responsible for delivering validated analytical chemistry methods and CMC documentation for OSIs regulatory submissions. In this role, he was responsible for collating and interpreting data from a wide range of analytical techniques, acquired in-house or at contract, for the characterisation of new compounds. There he also gained valuable international experience, working closely with regulatory and clinical groups as well as manufacturing and analytical contractors in Asia, Europe and the US.
Roland began his career in physical chemistry at Glaxo Group Research and originally specialised in chromatography, introducing the use of chiral HPLC columns to resolve enantiomers. He gained a PhD from his research into novel silicon-based chiral derivatisation reagents for HPLC, GC and NMR analysis. In 1998 he joined British Biotech, where he became involved in many other areas of analytical chemistry including polymorphism in pharmaceutical products. As Group Leader, he managed British Biotech’s QC procedures, stability testing and the analytical development of its NCEs.
Contact:
Dr Roland Collicott
ChalPharm Pharmaceutical Consultancy
Office: +44 (0)1753 885997
Mobile: +44 (0)7909 681661
Email: rcollicott@chalpharm.com
www.chalpharm.com
Dr Maria Marlow, Team Manager - Early Development,
AstraZeneca
Dr Maria Marlow obtained a pharmacy degree from Manchester University and PhD from Nottingham University in drug delivery. She then spent 2 years working at the Massachusetts Institute of Technology evaluating cell adhesion to polymers.
She started her industrial career in 1993 when she joined Fisons pharmaceuticals at the Loughborough site working on inhaled delivery systems. In 1996 she then lead a formulation team in product development that focused on developing metered dose inhalers & was involved in an NDA submission & technology transfer programme for Astra and then AstraZeneca.
Just over 4 years ago, she began work in early phase development working on poorly soluble compounds at the Alderley park site. In 2005 she joined the Preformulation and Biopharmacutics function at the Loughborough site during which time she represented the Pharmaceutical and Analytical R&D department on Discovery project teams as pre-clinical project leader on oral and inhalation projects. Since 2006 she has been managing a matrix team of formulation, analytical, material characterisation and biopharmaceutical scientists in the 'Early Development' function within Pharmaceutical and Analytical R&D. In these teams the focus is on the ‘developability’ of both inhalation and oral projects from a pharmaceutical perspective taking projects as efficiently as possible from the initial Drug Discovery stages through to first time in man phase 1 studies and regulatory submissions.
Dr Chris Hill, Vice President and Site Head, Newhouse,
Schering-Plough Corporation
Dr Chris Hill is Vice President and Site Head, Newhouse at Schering-Plough and is responsible for the research site in Scotland, comprising >300 staff.
Chris graduated in chemistry at the University of Manchester and undertook his PhD studies in synthetic chemistry at UMIST under the supervision of Professor Robert Ramage. He then moved to France for a postdoctoral research position with Professor Sir Derek Barton. In 1985 he returned to the UK and began his career in the pharmaceutical industry by joining Roche Research as a Team Leader in the Chemistry Department. After a brief spell at Parke-Davis in 1993-4, Chris returned to Roche as a Department Head in chemistry. He held a variety of positions over the next 7 years including Therapeutic Area Head for Inflammatory Diseases and Director of Chemistry. In 2001 Chris left Roche to join Organon as Executive Director of Medicinal Chemistry, and was appointed to his current position in July 2003.
Chris’ therapeutic interests have historically been in the areas of inflammatory and viral diseases. Current areas of research include CNS diseases, analgesia and cardiovascular disease.
Chris has played an active role in external organisations, particularly in the chemistry field. He has been a member of the RSC Organic Council and is currently a member of the SCI Fine Chemicals Group (formerly chair), ABPI R&D Committee and the Industry Advisory Group to the Scottish Executive. He was recently awarded a Distinguished Service Award by the SCI.
Dr Lloyd Payne, CSO,
F2G Ltd
Dr Lloyd Payne is currently responsible for drug discovery and early development activities within F2G Ltd, a UK-headquartered biotechnology company focused on the identification and development of novel therapeutics for the treatment of life-threatening fungal disease. F2G has successfully developed a range of core capabilities related to antifungal drug development including medicinal chemistry, ADME, microbiology, biochemistry, pharmacology, and fungal molecular biology based at its facilities in Manchester. In addition to its internal expertise, the Company has also built key relationships with several global and European CRO’s thus enabling a highly efficient and flexible approach to its scientific operations from early discovery through to later stage clinical development activities.
Lloyd was previously a senior scientist at Millennium Pharmaceuticals where he was responsible for the leadership of multidisciplinary drug discovery project teams based in the UK and the US. Lloyd provided direction for a number of medicinal chemistry programs from early hit validation through to late stage lead optimisation and has led several successful projects focused on the development of therapies for inflammatory disorders and cancer. Lloyd has also held senior scientific and management positions within Cambridge Discovery Chemistry Ltd and NCE Discovery Ltd where he was responsible for a number of collaborative medicinal chemistry projects working with organisations across Europe, Japan and the U.S.
Dr Steve Shuttleworth, Chief Scientific Officer,
Karus Therapeutics Ltd
Stephen joined Karus Therapeutics at Director of Research and Development in January 2008, and was recently appointed Chief Scientific Officer. Stephen has established a strong track-record in R&D management with a number of high-calibre companies on both sides of the Atlantic, including Celltech-Chiroscience (Cambridge, UK), Shire Pharmaceuticals Inc. (Montreal, Canada), Amgen, Inc. (San Francisco, California) where he was Associate Director of Chemistry, and Piramed Ltd. (Slough, UK) where he was Director of Chemistry and PI3K Programme Leader. Prior to joining Karus he was Head of New Projects Development at Cancer Research UK in London.
Stephen obtained his BSc and PhD in Chemistry at the University of Liverpool. He has authored more than 70 publications and patents, and is a Fellow of the Royal Society of Chemistry.
Ed Dutton, Business Development Manager,
Peakdale Molecular
Ed Dutton is Business Development Manager at Peakdale Molecular. He obtained a BSc in Medicinal Chemistry from Loughborough University which included a sandwich placement at GlaxoWellcome in Stevenage. Ed joined Peakdale Molecular in 2001 as a parallel synthesis chemist, and became part of the commercial team in 2003. He is now responsible for new business in UK, Western Europe and Japan.
David Bormett, Director Regulatory Affairs,
SAFC Pharma
Dave Bormett has over 15 years of experience in the pharmaceutical industry, focusing on quality assurance, quality control, validation, and regulatory affairs pertaining to the development and manufacture of drug substances in a GMP environment. He is currently the Director of Regulatory Affairs for SAFC Pharma in Madison, WI, USA, with responsibilities covering QA, QC, regulatory, health & safety, and facilities management. His range of experience includes quality and regulatory issues pertaining to preclinical drug substance development through commercialization, as well as health and safety issues pertaining to the handling of highly potent pharmaceutical compounds. He has been involved with the design and validation of several facilities and systems utilized for GMP drug substance manufacture and potent compound containment.
Dr Philippe Fernandes, Solid State Scientist,
Onyx Scientific
Philippe worked for six years as a research assistant at the Strathclyde Institute of Pharmacy and Biomedical Sciences in Glasgow. He was part of the Solid-State Research Group (SSRG), organised and run by Dr Alastair. Florence. The SSRG specialises in crystallographic investigations of pharmaceuticals, including all aspects of solid-state polymorphism, ranging from crystallisation, to phase transformations, through to crystal structure solution from single-crystal and powder X-ray diffraction data.
Philippe has joined Onyx-scientific to support and develop the solid-state service towards the pharmaceutical industry with the main theme to establish the state-of-the-art experimental facilities. Dedicated facilities include a suite of one XRPD instrument, an automated parallel crystallization, thermal analysis, Raman spectroscopy, microscopy, analytical techniques and solubility apparatus.
Philippe still works closely with Dr K. Shankland of the Data Analysis and Visualisation Group within the ISIS Facility at CCLRC’s Rutherford Appleton Laboratory and Dr A. Florence. The collaboration focuses on basic research including: (i) structure determination from synchrotron and laboratory (D8) powder diffraction and (ii) exploiting emerging technologies including information management systems, distributed computing and crystal structure prediction.
Pauline Jäger, Vice President Business Development,
Avantium Technologies
Pauline Jäger is Vice President Business Development for Europe at Avantium. After studying Chemistry at the Free University of Amsterdam, she joined the pharmaceutical industry where she has been active in various marketing and business development positions.
During her 20 years in the industry, she gained experience with several stages of drug development. She started her career at Glaxo/Glaxo Welcome, where she was involved in the marketing, sales and clinical trials of marketed drugs. Subsequently, at the Dutch research organization TNO, she was responsible for the development of contract research in preclinical pharmacology. Three years ago she joined Avantium where she is currently responsible for the business development of Solid State Research.
Dr John Blacker, Technical Director,
Piramal Healthcare
John is both Technology Director at NPIL Pharma (UK) Ltd, (1990 to date) and Technical Director at University of Leeds, School of Chemistry, spending 50% of his time in each role. Since 2004 Technology Director and senior scientist for NPIL Pharmaceuticals particularly involved in the identification, development, application and commercialisation of chemical and technologies including CATHy™, CACHy™ and SCRAM™ catalysts. Published >50 papers >30 patents. Skills include creative pharmaceutical route design, process design and development
Since 2007 Technical Director at University of Leeds (50% part-time) initiating and responsible for setting-up and running iPRD, Institute for Process Research and Development. Coordinating some of the activities of academics in chemistry and engineering and aligning with the needs of an industrial club consisting large, medium and small fine chemical companies.
Recent Career Highlights include Royal Society of Chemistry, Process Technology Award for work on chiral catalysts (2007), Successful Yorkshire Forward Large Company Scheme Award £1m project, Avecia Innovation Award for chiral catalysts (2003), and RSC Industrial Award for Teamwork associated with the invention, application and commercial use of CATHy™ catalysts (2002).
Dr Ben Cliff, Business Development Manager,
Intertek ASG
Dr Ben Cliff is a Business Development Manager within Intertek’s Pharmaceutical Services stream. He did a first degree in Chemistry with a sandwich year at Glaxo Wellcome, following this he went on to complete a PhD in surface analysis at Manchester. Ben then has worked in senior technical / commercial roles at both a scientific equipment manufacturer and an analytical services company prior to joining Intertek early this year. He is responsible for client liaison and technical project discussions in the pharmaceutical, biopharmaceutical and medical device segments.
Key Sponsors
Gold CRO Sponsors
Silver CRO Sponsor
Corporate Sponsor
